Plain-English translation of NCT05595447 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a treatment strategy using brentuximab (a targeted cancer drug) combined with a type of immunotherapy called PD-1 blockade to help your immune system fight Hodgkin lymphoma. If the cancer responds well to this medication combination, you would then receive a stem cell transplant followed by more cycles of the same treatment to try to keep the cancer from coming back.
About half of patients with hard-to-treat Hodgkin lymphoma don't get better with standard chemotherapy, and doctors need better options. This trial exists because this new medication combination appears to work well against this type of lymphoma and may cause fewer serious side effects than current standard treatments.
You likely qualify if…
You likely don't qualify if…
You would receive eight cycles of the medication combination (brentuximab plus immunotherapy) as an outpatient, followed by a stem cell transplant procedure at a hospital. After recovery from the transplant, you would receive eight more cycles of the same medication combination as maintenance therapy. Throughout the trial, you would have regular blood tests, scans, and check-ins with your medical team to monitor how you're responding and watch for any side effects.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
Mexico